With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...

Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug ... called GLP-1 ... Nov. 12, 2024 — Obesity causes ...